✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Glaxosmithkline Pharmaceuticals Ltd.

GLAXO

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹46,591 Cr.
P/E
49.03

Glaxosmithkline Pharmaceuticals Ltd.

  • Glaxosmithkline Phar
  • Glenmark Pharma
  • Ipca Laboratories
  • TJI Pharma

FAQs on Glaxosmithkline Pharmaceuticals Ltd. Shareprice

Glaxosmithkline Phar has given better returns compared to its competitors.
Glaxosmithkline Phar has grown at ~17.35% over the last 4yrs while peers have grown at a median rate of 10.59%

Yes, Glaxosmithkline Phar is expensive.
Latest PE of Glaxosmithkline Phar is 49.16, while 3 year average PE is 48.04.
Also latest EV/EBITDA of Glaxosmithkline Phar is 37.82 while 3yr average is 35.66.

View FAQ's On Business

Growth Table

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Ipca Laboratories

Balance Sheet

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Ipca Laboratories

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Ipca Laboratories

Cash Flow

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Ipca Laboratories

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Ipca Laboratories

Quarterly Results

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Ipca Laboratories

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Glaxosmithkline Pharmaceuticals Ltd. Financials

Balance sheet of Glaxosmithkline Phar is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Glaxosmithkline Phar is decreasing.
Latest net debt of Glaxosmithkline Phar is -₹2,807.03 Crs as of Mar-25.
This is less than Mar-24 when it was -₹2,126.44 Crs.

Yes, profit is increasing.
The profit of Glaxosmithkline Phar is ₹950 Crs for TTM, ₹928 Crs for Mar 2025 and ₹590 Crs for Mar 2024.

The company seems to pay a good stable dividend.
Glaxosmithkline Phar latest dividend payout ratio is 98.62% and 3yr average dividend payout ratio is 93.09%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech